Exclusion criteria~* Pregnant or breastfeeding~* Inability to tolerate magnetic resonance imaging (MRI)
procedures or contraindication to MRI~* Contraindications to both PET imaging and lumbar dural puncture (must
be able to undergo at least one of these procedures to be eligible)~* Residence in a skilled nursing facility~*
Any serious medical condition or abnormality in clinical laboratory tests that remains abnormal on retest and,
in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or
bias the assessment of the clinical or mental status of the participant to a significant degree~* Any evidence
of a condition other than AD that may affect cognition~* Alcohol or substance abuse within the past 2 years~*
Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater and any
passive immunotherapy (immunoglobulin) against tau, except use of RO7105705 in Genentech Study GN39058, as long
as the last dose was at least 90 days prior to screening~* Use of any passive immunotherapy (immunoglobulin)
against AÎ², unless the last dose was at least 1 year prior to screening and any active immunotherapy (vaccine)
that is under evaluation to prevent or postpone cognitive decline~* Any previous treatment with medications
specifically intended to treat Parkinsonian symptoms or any other neurodegenerative disorder within 1 year of
screening~* Systemic immunosuppressive therapy within 12 months of screening through the entire study period~*
Typical antipsychotic or neuroleptic medication within 6 months of screening~* Daily treatment with any of the
following classes of medication, except for intermittent short-term use, which is permitted except within 2
days or 5 half-lives (whichever is longer) prior to any COA: atypical antipsychotics, opiates or opioids,
benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting
antihistamine or anticholinergic activity~* Stimulant medications, unless the dose has been stable within the 6
months prior to screening and is expected to be stable throughout the study
